Legacy Wealth Asset Management LLC Lowers Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Legacy Wealth Asset Management LLC lowered its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 9.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,139 shares of the medical equipment provider’s stock after selling 944 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Lantheus were worth $1,003,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of LNTH. Vanguard Group Inc. raised its holdings in Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock valued at $458,271,000 after buying an additional 389,828 shares during the period. Farallon Capital Management LLC raised its stake in shares of Lantheus by 53.7% in the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after acquiring an additional 796,000 shares during the period. Westfield Capital Management Co. LP raised its stake in shares of Lantheus by 25.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock valued at $121,867,000 after acquiring an additional 394,837 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Lantheus by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after acquiring an additional 19,071 shares during the last quarter. Finally, Swedbank AB boosted its position in shares of Lantheus by 21.1% during the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after purchasing an additional 125,843 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LNTH. B. Riley boosted their target price on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. JMP Securities decreased their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. Truist Financial dropped their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Finally, Leerink Partners lifted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the transaction, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mary Anne Heino sold 10,481 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the transaction, the director now owns 454,923 shares in the company, valued at $43,445,146.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,981 shares of company stock valued at $2,689,156. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Up 0.4 %

Shares of Lantheus stock opened at $110.30 on Friday. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a market capitalization of $7.66 billion, a P/E ratio of 18.08 and a beta of 0.50. The company has a 50 day moving average of $107.32 and a 200 day moving average of $92.71.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $394.10 million for the quarter, compared to analysts’ expectations of $382.12 million. During the same period last year, the firm posted $1.40 earnings per share. Lantheus’s revenue for the quarter was up 22.5% on a year-over-year basis. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.